Targeted Medical Pharma is focused on product development in areas with the greatest medical and commercial promise. We are committed to developing medications for diseases where the current treatment modalities are ineffective or associated with adverse side effects. Our current pipeline is focused on addressing chronic pain and inflammation, asthma, anemia, autism, obesity, diabetes, posttraumatic stress disorder and other diseases of the nervous system.
Therapeutic Area Product Name Product Class Commercialization Pain and inflammation (chronic) Theramine® Medical Food Complete Pain and inflammation (arthritis) Trepadone® Medical Food Complete Pain and inflammation (neuropathy) Percura® Medical Food Complete Sleep disorders associated with depression, PTSD, fibromyalgia Sentra PM® Medical Food Complete Sleep disorders associated with anxiety GABAdone® Medical Food Complete Chronic fatigue, pain, cognitive disorders Sentra AM® Medical Food Complete Obesity AppTrim® Medical Food Complete Hypertension Hypertensa® Medical Food Complete Viral infection, impaired immunity Lister V® Medical Food Complete Nasal Congestion/Snoring ClearWayz™ Dietary Supplement Complete Autism, autism spectrum disorders Auspect™ Medical Food TBD Asthma Pulmona New Medical Food TBD
8k Yesterday
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 6, 2017, Mr. Kim Giffoni tendered his resignation as Interim Chief Executive Officer of Targeted Medical Pharma, Inc. (the “Company” ) to focus on other business activities. At the time of his resignation, Mr. Giffoni served as Interim Chief Executive Officer and Director. Mr. Giffoni will remain a member of the Company’s Board and will serve as the Company’s Executive Vice President of Foreign Sales. Mr. Giffoni did not resign as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).Emerging growth company ¨If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
An interim Chief Executive Officer, Marcus Charuvastra, the Company’s former VP of Operations and Marketing and a current Director has been appointed by the board.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 12, 2017
TARGETED MEDICAL PHARMA, INC.
By: /s/ Marcus Charuvastra Name: Marcus Charuvastra Interim Chief Executive Officer
Your stock trades are your own responsibility. No one forces you to make the trade. Always take responsibility for your own decisions and you will never have anyone else to blame
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.